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 Abstract 
 
Objective 
Few studies have investigated the role of inflammation in Lewy Body Dementia (LBD) and 
variable results have been found. We systematically reviewed the literature for evidence of 
systemic inflammatory changes in Dementia with Lewy Bodies (DLB) and Parkinson’s Disease 
Dementia (PDD). Due to the low number of studies we also included Parkinson’s disease (PD). 
 
Methods 
Key terms were used to search the relevant databases. Titles and abstracts were screened and 
potentially relevant articles were reviewed in full. References of included studies and relevant 
reviews were searched. 
 
Results 
The database search returned 2166 results, 46 of which were finally included in the systematic 
review. These studies showed a general increase in inflammatory markers in the peripheral 
blood, most notably interleukin-1beta, tumor necrosis factor-alpha, interleukin-6 and interleukin-
10. Studies examining cerebrospinal fluid (CSF) found interleukin-1beta, interleukin-6 and 
transforming growth factor-beta1 to be particularly increased, and interferon-gamma decreased. 
C-reactive protein levels were increased, particularly in PDD.  
 
Conclusions 
These results provide evidence that LBD is associated with an increased inflammatory 
response. Furthermore, there may be a stronger general inflammatory response in LBD than in 
PD, whilst complex changes occur in the individual cytokines.   
 
 
Keywords: Lewy Body Dementia, Parkinson’s Disease, Inflammation, Cytokines, Systematic 
review 
 
 
 
Introduction 
The Lewy body dementias (LBD) are amongst the most common causes of dementia, 
second only to Alzheimer’s disease. LBD includes dementia with Lewy bodies (DLB) and 
Parkinson’s disease dementia (PDD), two closely related but clinically distinct causes of 
dementia. DLB describes dementia that occurs before or within 1 year of Parkinson’s 
disease, and is characterised by fluctuating cognitive function, visual hallucinations and 
parkinsonism1. PDD is dementia occurring in the context of established Parkinson’s 
disease2.  
Although the aetiology of LBD is not clear, it seems likely that inflammation plays a role in 
the pathogenesis of the disease. There is extensive evidence to support the role for chronic 
inflammation in Alzheimer’s disease (AD) in animal studies and postmortem studies of the 
brain3 and in studies of peripheral biofluids4. There have been far fewer investigations of the 
role of inflammation in LBD, however because inflammation seems to be important in 
dementias such as Alzheimer’s disease, it may also have a role in LBD. For example, it has 
been shown that Interleukin (IL)-6 is correlated with both cognitive decline5 and poorer 
baseline function in patients with DLB, and furthermore Tumor Necrosis Factor (TNF)-alpha 
appears to be associated with an increase in neuropsychiatric features6. A longitudinal study 
of Parkinson’s disease patients found that a higher level of IL-6 was associated with an 
increased risk of Parkinson’s disease 4 years later7, and chronic use of non-steroidal anti-
inflammatory drugs has been found to reduce the risk of PD by around 45 %8. This evidence 
strongly supports the theory for an inflammatory component in the pathogenesis of both LBD 
and Parkinson’s disease (PD).  
Cytokines are large soluble proteins which act to communicate with immune cells and 
coordinate inflammatory responses, and are commonly used in studies as markers of 
inflammation. Furthermore, CRP is a common clinical marker of inflammation. Therefore we 
conducted a systematic review of the literature for evidence of systemic inflammation by way 
of raised cytokine and C-reactive Protein (CRP) levels in DLB and PDD. However, due to 
the low numbers of studies available we also included PD patients as this encompassed a 
wider array of studies, and provided more information about inflammation in Lewy body 
diseases.  
 
 
 
Methods 
Search Strategy 
We used the databases MEDLINE, EMBASE and PsycINFO to search for all relevant 
papers, up to and including 26th August 2016. Key terms used for the search were: 
• Lewy body OR lewy bodies OR Parkinson’s disease AND 
• Inflammation OR inflammatory OR cytokines OR biomarkers AND 
• Systemic OR peripheral OR serum OR blood OR CSF OR cerebrospinal fluid 
Search criteria was specified to human studies only. Titles and abstracts were screened and 
potentially relevant articles were reviewed in full. References of included studies and 
relevant reviews were also searched to ensure all relevant studies were included. 
 
Included Studies 
Original studies measuring cytokine concentration in living patients who had been given a 
formal diagnosis of either Parkinson’s disease, Parkinson’s disease dementia or dementia 
with Lewy bodies were included. Studies must have had a comparison healthy control group 
of subjects without any signs or symptoms of Lewy body disease. We only included studies 
investigating levels of cytokines and CRP in serum, plasma or CSF and all other markers of 
inflammation were excluded from our search. Studies measuring cytokine levels from 
peripheral blood and cerebrospinal fluid (CSF) were reviewed separately, as were those 
measuring cytokines from patients with Parkinson’s disease, Parkinson’s disease dementia 
and dementia with Lewy bodies. Animal studies, non-English literature and post-mortem 
studies were not included.  
Data extraction 
Data was extracted from all included papers and entered into an excel spreadsheet. 
Information was collected relating to participant demographics, cytokines measured, study 
design, inclusion and exclusion criteria and key findings.  
 
Results 
Literature Search Findings 
The initial search yielded 3054 studies from the three databases. There were 888 duplicate 
studies, leaving 2166 results after these duplicates had been removed. From screening titles 
and abstracts 2079 studies were excluded. This left 87 articles for review. Excluded articles 
were mainly review articles or book chapters, imaging studies, postmortem studies, different 
inflammatory makers, and remaining animal and duplicate studies which had been missed 
by the database filter.  
87 full text articles were reviewed and 49 of these were excluded. Excluded articles mainly 
comprised of conference articles, studies with no control group, studies not measuring 
cytokines, and studies not written in English. A total of 38 studies were suitable for the 
systematic review. Hand-searching included references and relevant reviews yielded a 
further 8 papers which were suitable, leading to a total of 46 included studies. See figure 1 
for summary.  
 
Demographics 
The patient populations in the studies were variable and sample sizes were highly variable, 
with the largest study consisting of 435 patients9 and the smallest consisting of just 8 
patients10. The age of the patients varied by almost 30 years, with the youngest patients 48 
(+/- 8.3)11, and the oldest 76 (+/-5)12. Disease duration also varied significantly, ranging from 
de novo disease patients9,10,13-15 to patients with a mean disease duration of 15.8 (+/- 6.5) 
years16. Medications taken by patients were again variable; the maximum mean amount of 
levodopa usage was 1072.67 (+/-552.69) mg17, whilst in some studies no medications were 
being used by any of the patients9,18-20.  
Patients with PD were investigated in 44 of the 46 studies. Dementia with Lewy Bodies was 
investigated in 2 studies, PDD was investigated in 4 studies and PD with mild cognitive 
impairment (PD-MCI) was investigated in one study. The patients with PDD and DLB were 
on average older than the PD patients. 
30 studies investigated cytokine levels in peripheral blood, 10 studies measured cytokine 
levels in CSF, and 6 additional studies were measuring both peripheral blood and CSF. 
Studies measuring CRP levels included 10 peripheral blood studies and 1 CSF study. 8 of 
these studies were measuring CRP alone and the other three were also measuring 
cytokines. The two studies by Rentzos21,22 were classified together, as were two of the 
studies by Mogi23,24 as the same cohort of patients and controls was used for both of these 
sets of studies.  
 Peripheral blood studies 
Of the studies investigating cytokine levels in peripheral blood, 23 were using serum 
samples10-13,16,17,21,22,25-40 and and 4 used plasma samples14,18,41,42. There were no noticeable 
differences between the findings from the serum and plasma samples, so these were 
grouped together as ‘peripheral blood. All peripheral blood studies used Parkinson’s disease 
for their patient group and none investigated patients with DLB, PDD or PD-MCI.  
Of the peripheral blood studies, there was a general overall increase in cytokine levels in 
patients with PD, with IL-1beta, TNF-alpha, IL-6 and IL-10 showing the largest overall 
increase. However almost equal numbers of studies found non-significant differences in 
each of these cytokines. There was an overall increase in pro inflammatory markers IL-2, IL-
12 and IL-15 and the anti-inflammatory marker IL-4, though a large proportion of the studies 
investigating these cytokines also found no significant difference between patients and 
controls. The only cytokine to show a slight overall decrease in peripheral blood in patients 
compared to controls was IL-8. Table 1 shows results of all cytokines that were measured in 
more than one study.  
Only one study investigated peripheral blood cytokine levels in LBD, and found no significant 
difference in levels of IL-12, IL-10, INF-gamma or transforming growth factor (TGF)-beta1 in 
the 10 PDD patients in their cohort compared to controls28.  
In addition to table 1, Brockmann found no significant difference in levels of IL-16, however 
there was a significant difference in IL-18 levels in the male Leucine-rich repeat kinase 2 
(LRRK2) group, but not the idiopathic parkinson’s disease group37.  
 
Cerebrospinal fluid samples 
Of the 14 studies investigating CSF, 12 were investigating patients with Parkinson’s 
disease10,13,16,18,23,24,35,36,43-47. Three of these studies also investigated patients with 
PDD16,45,46, one of which further included PD-MCI patients45. Two studies investigated 
patients with DLB only48,49. Two studies were using ventricular CSF as their biofluid which 
was collected prior to stereotaxic surgery23,24 and these two studies were grouped together 
as they used the same cohort of participants. All other studies used lumbar CSF as their 
biofluid.  
In the CSF some cytokines showed a general increase, whilst others decreased. Apart from 
one study in which IL-1beta could not be detected, IL-1beta was increased in all studies, 
though this was only significant in 5 of the studies. TGF-Beta1 was significantly increased in 
patients in both of the study investigating it. INF-gamma was decreased patients compared 
to controls, and varying results were found in studies investigating TNF-alpha, with the 
majority of studies finding no significant differences between patients and controls. IL-2 was 
only investigated in 2 studies, only one of which found a significant difference. IL-4 only 
appeared in one study which found no significant difference. Results of all cytokines which 
were measured in more than one study of CSF are presented in table 2. Also included are 
cytokines only measured in one CSF study if they had also been measured in peripheral 
blood to allow comparisons to be made.  
In LBD, increased IL-8 appeared to be associated with PDD, and lower levels of IL-6 was 
associated with DLB. Increased IL-6 and IL-1beta and lower levels of TNF-alpha was 
associated with PD-MCI.  
Some studies also investigated cytokines that had not been investigated in any other 
studies, and therefore the results of these were not presented in table 2. Martin de Pablos 
found no significant difference in TGF-Beta2 levels47, and Mogi found no difference in TGF-
alpha levels24, whilst both found an increase in TGF-beta1 levels. Furthermore, Choi found 
no significant differences between patients and controls in IL-5, IL-7 or IL-1310. 
 
CRP levels 
Of the 11 studies investigating CRP only one study used CSF16, and all others measured 
CRP in peripheral blood9,15,19,20,39,50-54. All studies were investigating CRP levels in patients 
with PD, and two studies also investigated PDD patients.  
In general these studies found an increase in CRP levels in patients in comparison to 
controls, with 7 finding a significant increase. Having a diagnosis of PDD also appeared to 
be associated with raised CRP levels. One study found significantly higher CRP levels in 
PDD patients but not in PD patients16, and the other found a significant increase in both 
patient groups compared to controls, but a larger increase in PDD patients than in PD 
patients15. In addition, a study which found significantly higher levels of CRP in PD patients 
who experience hallucinations found that this sub-set of patients also had a lower MMSE 
score, which may further be correlated to the higher CRP levels52.  These studies therefore 
imply that there may be an association between CRP levels and PD progressing to PDD.  
 
 
Discussion 
 
We reviewed the literature for evidence of systemic inflammation in PD and LBD, specifically 
looking at studies of cytokine levels as a commonly used marker of inflammation in 
research, and CRP levels as a common clinical marker of inflammation. We found a general 
increase in cytokines in the peripheral blood and in the CSF, with cytokines such as IL-
1beta, IL-6, TNF-alpha and IL-10 being particularly increased in the peripheral blood, and IL-
1beta, IL-6 and TGF-beta1 being particularly increased in the CSF. In the peripheral blood, 
there were no cytokines which were consistently decreased, whilst in the CSF INF-gamma 
was decreased in both studies. CRP levels were generally increased in patients with PD and 
PDD. Therefore, we found that overall there is an increased inflammatory response in 
patients with LBD and PD.  
 
LBD had an increased inflammatory response compared to PD, with PDD patients having 
higher levels of CRP in blood and in CSF. Previously, increased CRP levels have been 
associated with dementia55 and CRP has been correlated with cognitive deterioration in 
patients with MCI56, making it likely that increased CRP levels may correlate with cognitive 
decline. However, more complex changes appear to occur in individual cytokines in LBD; IL-
1beta was increased in patients with PD-MCI45, and was also inversely correlated with 
MMSE scores in PD patients34 something which is also found in other types of dementia57. 
However, there was no significant difference in IL-1beta levels in DLB. Furthermore IL-6 was 
decreased in the DLB study49, whilst being increased in PD-MCI45. These findings suggest 
that the levels of cognitive impairment and parkinsonism combined may impact on the role 
that each individual cytokine plays in the disease pathogenesis.   
 
The most commonly studied cytokines were the pro-inflammatory cytokines TNF-alpha, IL-
1beta and IL-6. Studies have also reported increased levels of these cytokines in the brain in 
PD patients, suggesting that they are likely to be playing a role in the neuroinflammatory 
processes43,58-60. IL-1beta was the most consistently increased cytokine. In all peripheral 
blood and CSF studies whereby IL-1beta could be detected an increase was found, and the 
studies which found non-significant increases tended to have high standard deviation. IL-1 
has potent effects on the brain both systemically whereby it induces sickness behaviour61 
and in the CNS, where it has been implicated in both acute brain injury62, and chronic 
neurodegeneration, particularly in AD63. Furthermore, LPS-mediated IL-1beta elevation has 
been shown to potentiate the amount of DA neuronal loss in rats64. From the evidence 
gathered in this systematic review, it is likely that IL-1 is playing a role in the pathogenesis of 
PD and LBD. 
 
IL-6 is involved in inducing acute phase reactions, and has been the most commonly studied 
cytokine in PD and LBD. IL-6 has opposing properties; when up-regulated by IL-1beta and 
TNF-alpha IL-6 has a pro-inflammatory role, precipitating neuronal degeneration and cell 
death65. When IL-6 induces the IL-1 receptor antagonist and IL-10, this triggers neuronal 
survival66,67. Generally there was an increase in IL-6 in peripheral blood and CSF, though 
many studies found no significant difference. As IL-6 acts as both a pro-inflammatory and 
anti-inflammatory cytokine its role in PD may change with disease progression, age or with 
L-Dopa use.  
 
TNF-alpha is also involved in acute phase reactions, and plays a key role in several 
autoimmune diseases, with TNF-alpha inhibitors being used in the management of 
conditions such as rheumatoid arthritis, alkalising spondylitis, psoriasis and inflammatory 
bowel disease. In the studies reviewed, levels of TNF-alpha tended to be increased, 
however a study of PD-MCI patients found decreased levels of TNF-alpha in the CSF, which 
may be a compensatory mechanism to prevent deterioration to PDD45. It is plausible 
therefore TNF-alpha may be implicated in the progression from PD towards PDD.  
 
The anti-inflammatory cytokine IL-10 was also consistently raised in the periphery of patients 
with PD, being significantly increased in most cases, which may be a compensatory 
mechanism in response to high levels of pro-inflammatory cytokines21,22,37. IL-10 was not 
measured in the CSF, however TGF-beta1 was consistently increased in the CSF which 
correlated with UDPRS motor score. As TGF-beta has pro- and anti-inflammatory properties, 
it may be that that TGF-beta1 is acting in a pro-inflammatory manner to worsen disease 
progression, or it may be acting to compensate for worsening disease47.  
 
Other factors influencing inflammatory markers 
 
It is evident from these studies that even when using similar methods and diagnostic criteria 
there is wide variation in results, likely due to individual differences impacting on cytokine 
levels. For example, cytokines have been found to vary depending on age, with increased 
inflammatory markers playing a role in ageing and mortality in healthy elderly individuals68, 
and associations being found between age and TNF-alpha, IL-625, the soluble TNF-alpha 
receptor169, IL-1beta27 and CRP levels70. Age of onset of disease may have an impact on 
cytokine variation; one study found higher levels of cytokines in juvenile PD than in late 
onset PD, suggesting that a more intense inflammatory reaction may result in earlier PD 
symptoms24. Gender may affect baseline cytokine profile, with increased pro-inflammatory 
cytokine mRNA expression being found in the striatum of male mice compared to females71. 
In humans, males have a more pronounced response to inflammation than women72. In PD 
patients, Brockmann found that whilst males had a higher level of the pro inflammatory 
cytokine TNF-alpha and IL-6, females had higher levels of IL-4 and IL-12p40, implying that 
gender may indeed lead to variation in cytokine levels37.   
 
Medication and disease severity have also been associated with variation in cytokine 
profiles. Gangemi found that only patients who were being treated with Levodopa had 
increased levels of cytokines26, and a study of PBMC found that levodopa was able to 
enhance IL-6 and TNF-alpha secretion73, suggesting that the actions of levodopa are in part 
immuno-modulatory. It may however be that these findings are a result of increased disease 
severity in patients taking levodopa, as studies have found that worse motor symptoms 
correlate with IL-6 and TNF-alpha39,42. However, Muller found an inverse correlation between 
IL-6 and motor symptoms44 and Selikhova found that IL-6 correlated with faster progressing 
disease41, suggesting that there are more complex cytokine interactions at play.  
 
Therefore it seems likely that many factors affect baseline cytokine levels, and this may in 
part explain the variable results found between studies. Neuroinflammation is a complex 
network of cytokine interactions, something which is likely to vary depending on the health 
and demographics of the individual. Therefore this must be taken into consideration when 
studying cytokines in disease.  
 
 
 
Mechanisms of systemic inflammation and its effect on neuroinflammation in PD 
 
The importance of this systemic pro-inflammatory response and the impact that it has in PD 
and LBD has been investigated. It has been suggested that a systemic immune event may 
precede clinical parkinsonism, allowing a pathogenic stimulus to PD to take advantage25. 
Constipation often precedes a diagnosis of PD74, and many PD patients have small bowel 
bacterial overgrowth on presentation75 suggesting the GI tract might be the source of the 
inflammation. Prenatal inflammation in rats can lead to an altered inflammatory response 
and a progressive loss of dopaminergic neurones, suggesting that prenatal infections may 
be a risk factor for later PD76.  
 
Peripheral Blood Mononuclear Cells (PBMC) have been studied as a potential cause of the 
exaggerated inflammatory profile in patients with PD. Studies have found impaired 
production of IL-2 by PBMCs73,77, whilst over-production of others has been found78,79, 
suggesting that dysregulation in PBMCs may play a role in the altered inflammatory profile. 
 
Theories as to how systemically elevated cytokine levels are able to interact with the CNS 
have been suggested. Possible mechanisms include communication via the vagus nerve to 
the nucleus of the solitary tract80,81, direct communication with macrophages in the 
circumventricular organs 82, and communication via endothelial cells lining the BBB83. 
Through these pathways, peripheral cytokines may have the ability to communicate with the 
CNS to induce or potentiate the neuroinflammation seen in PD. 
 
 
Clinical importance 
 
Clinically, the findings from these studies are likely to be important in optimising 
management in PD and LBD by focussing on the inflammatory aspect of the disease 
pathology. Animal studies have investigated the effects of non-steroidal anti-inflammatory 
drugs (NSAIDs) in models of PD, and aspirin, ibuprofen and COX-2 selective inhibitors have 
been repeatedly shown to exert neuroprotective effects84. Dexamethasone treatment has 
been found to diminish neuronal damage following MPTP administration85 and minocycline 
has been shown to prevent MPTP-induced microglial activation and decrease the production 
of inflammatory cytokines in mouse models of PD86.  
 
In human studies, Chen found that regular use of NSAIDs reduces the risk of Parkinson’s 
disease by about 45%8, with a dose-dependent risk reduction with ibuprofen use87. A 
systematic review showed that non-aspirin, non-steroidal anti-inflammatory drug use is 
associated with a 15% reduction in risk of PD, which is increased to 29% reduction with 
regular use88. Currently, no studies have investigated the use of NSAIDs as a treatment of 
established PD. Again in AD, observational studies have found that NSAID use reduces the 
risk of later AD89, however clinical trails investigating the use of NSAIDs in dementias such 
as AD have yielded disappointing results. A systematic review including seven clinical trials 
found that there was no difference in cognitive decline with NSAIDs compared to placebo90. 
These findings indicate that any benefits of using NSAIDs in AD, and likely also in PD and 
LBD may be early in disease pathogenesis, possibly at the pre-symptomatic stage.  
 
Currently, the use of anti-inflammatory medications to reduce the risk of PD is limited due to 
the difficulty in predicting PD cases. Further research into establishing the effect of using 
anti-inflammatory medications in patients with established disease is needed. 
 
 
 
 
Limitations 
 
There are several limitations to this study which must be taken into account. Firstly, the 
literature search was limited to cytokines and CRP, therefore studies involving chemokines, 
inflammatory proteins, soluble inflammatory receptors and other inflammatory molecules 
were excluded from the search criteria. Furthermore, the biofluid in the search was limited to 
plasma, serum and CSF. Studies stimulating PBMC were excluded, as were any studies 
looking at cytokine levels in the brain. Further work should be undertaken to review the 
literature in respect to these factors.  
 
Methodology was another limiting factor in this study. Whilst the majority of the studies used 
ELISA to analyse biofluids, other techniques included cytometric bead array, MSD and 
luminex. This variation in methodology may have led to differences in results obtained.  
 
 
 
Conclusions  
 
This systematic review suggests that there is a pro-inflammatory response in the CSF and 
the peripheral blood in patients with PD and LBD, and furthermore that increased 
inflammation appears to be correlated with progression of PD towards PDD. In particular, IL-
1beta was consistently increased across all studies, making it likely that it is playing a key 
role in disease progression. It is however it is evident that there is a lack of studies 
investigating systemic inflammation in LBD, particularly in peripheral blood, and therefore 
there is a need for further research to investigate this. The information obtained in this 
review is of high clinical value as it suggests that anti-inflammatory medication may be 
useful in management of LBD, and although studies have found a correlation between anti-
inflammatory medication use and increased risk of Parkinson’ s disease, there is a need for 
further work to investigate the use of anti-inflammatory medication in established LBD.   
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Figure 1: Flow chart of studies through screening 
Table 1 
Study 
Number of 
participants 
Disease 
Duration 
(years) Age (years) Method used 
Pro-inflammatory Variable Anti-inflammatory 
IL-
1alpha IL-1beta IL-2 IL-8 IL-12 IL-15 
TNF-
alpha 
INF-
gamma IL-6 
TGF-
beta1 IL-4 IL-10 
Pirttila 1994 
(14) 
 
20 PD 
42 Controls 
 
New onset 
 
 
PD: 64.6 
control: 60.9 
 
ELISA 
 
  
NS 
 
           
Hu 2015 (36) 
210 PD 
31 Control 
2.3 
 
PD: 60.2 
Control: Matched 
ELISA 
  
↑*** 
     
NS 
      
Hu 2015 (37) 
225 PD 
31 Controls 
2.2 
 
PD:59.0 
Control: Matched 
ELISA 
 
  
↑*** 
     
↑* 
      
Koziorowski 
2012  (18) 
60 PD 
24 Controls 
11.2 
 
PD: 59.2 
Control: 64.0 
cytokine multiplex 
kit  
NS 
  
NS 
 
NS 
  
↑*** 
  
NS 
   
NS 
 
Williams-Gray 
2016 (40) 
230 PD 
93 Controls 
0.6 
 
PD: 66.4 
Control:68 
MSD 
  
↑*** 
 
↑*** 
 
NS 
 
NS 
  
↑*** 
 
NS 
 
NS 
   
↑*** 
 
Dursun  2015 
(35) 
40 PD 
32 Controls 
Not 
specified 
PD: 71.0 
Control: 72.1 
ELISA 
 
↓* 
 
↑** 
       
↓*** 
    
Blum-Degen 
1995 (19) 
22 PD 
12 Controls 
0.5-3.0 
 
PD: 61.0 
Control: 61.0 
ELISA 
  
NS 
 
NS 
      
NS 
    
Brockmann 
2016 (38) 
144 iPD, 
142 PD LRRK2 
133 Controls 
7 
10.5 
 
iPD: 68.5 
PD LRRK2: 66.0 
Control: 57.5 
Multiplexed 
immunoassay  
↑* 
NS 
  
{↓*} 
NS 
 
↑**(*) 
(↑*) 
  
NS 
NS 
  
{↑*} 
(↑**) 
  
NS 
NS 
 
↑*** 
NS 
 
Rota 2006 (29) 
14 PD 
25 Controls 
3.0 
 
PD: 66 
Control: 69 
ELISA 
     
NS 
   
ND 
  
NS 
  
NS 
 
10 PDD 7.2 PDD: 69 ELISA     NS   ND  NS  NS 
Da silva et al 
2015 (41) 
21 PD 
21 Controls 
6.0  
 
PD: 59.0 
Control: 59.0 
Cytometric bead 
array  
NS 
  
NS 
   
NS 
  
NS 
    
Zakarya 2004 
(28) 
30 PD 
20 Controls 
Not 
specified 
PD: 65.4 
Control: Matched 
ELISA 
  
↑*** 
  
↑*** 
   
↑*** 
  
↑*** 
    
Stypula 1996 
(15) 
21 PD 
25 Controls 
Recent 
onset 
PD: 64.6 
Control: Matched 
RIA 
 
↑** 
 
NS 
      
NS 
    
Gupta  2016 
(39) 
81 PD 
83 Controls 
3.2 
 
PD: 58.5 
Control: 57.6 
ELISA 
    
↓*** 
   
↓*** 
      
Brodacki 2008 
(30) 
31 PD 
20 Controls 
6.9 
 
PD:61.5 
Control:67.0 
Cytometric bead 
array   
↑** 
    
↑** 
 
↑** 
 
↑** 
  
↑** 
 
↑** 
 
Gruden  2012 
(34) 
32 PD 
26 Control 
1-5 
 
PD: 60.8 
Control: 63.0 
ELISA 
      
↑(153%) 
 
↓(100%) 
 
↑(444%) 
     
Lindqvist 2012 
(52) 
86PD 
40 Controls 
6.9 
 
PD: 64.2 
Control: 64.8 
Chemoiluminescent 
assays       
NS 
  
↑* 
    
Dobbs 1999 
(26) 
78 PD 
140 Controls 
Not 
specified 
PD: 69.4 
Control: 61.4 
ELISA 
       
NS 
  
NS 
    
Scalzo  2009 
(32) 
46 PD 
23 Controls 
7.5 
 
PD: 65.8 
Control: 61.9 
ELISA 
       
NS 
      
Scalzo  2010 
(33) 
44 PD 
22 Controls 
7.4 
 
PD: 65.7 
Control: Matched 
ELISA 
         
↑* 
    
Tang 2014 (13) 
78 PD 
80 Controls 
5.5 
 
PD: 76.3 
Control:75.4 
ELISA 
         
↑** 
    
Hofmann 2009 
(31) 
23 PD+LDopa 
17 Untreated 
23 Controls 
8.1 
2.8 
 
PD+LDopa:66.5 
Untreated: 65.3 
Control:60 
ELISA 
 
         
NS 
NS 
    
Selikhova 2001 
(42) 
45 PD 
15 Controls 
Not 
specified 
PD: 68.2 
Control: 62.5 
ELISA 
         
NS 
    
Varani 2010 
(43) 
56PD 
60 Controls 
5.5 
 
PD: 74.2 
Control: 71.4 
ELISA 
       
↑** 
      
Choi 2008 (11) 
8 PD 
13 Controls 
De novo 
 
PD: 73.0 
Control: 68.5 
Luminex xMAP 
 
NS 
 
ND 
 
ND 
 
NS 
 
NS 
 
ND 
 
NS 
 
NS 
 
ND 
  
NS 
 
ND 
 
Rentzos 2007 
(22) & Rentos 
2009 (23) 
41 PD 
19 Controls 
4 
 
PD: 67.5 
Control: 65.8 
ELISA 
     
NS 
 
NS 
      
↑** 
 
Fattah 2011 
(12) 
30 PD 
20 Controls 
10 
 
PD: 48.0 
Control: 47.1 
ELISA 
      
↑** 
      
NS 
 
Gangemi  2003 
(27) 
12 PD+Ldopa 
12 untreated 
12 Controls 
7 
2.2 
 
L-Dopa: 65.2 
Untreated: 58.4 
Control: matched 
ELISA 
      
↑* 
NS 
       
 
 
 
Table 1: All studies investigating cytokine levels in peripheral blood whereby authors in italics used plasma and all other authors used serum. It 
is indicated whether there is a significant increase or decrease, where * = p < 0.05, ** = p < 0.01, *** = p < 0.001, NS = non-significant and ND 
= cytokine not detected. ELISA = Enzyme-linked immunosorbent assay, MSD = Meso Scale Discovery, RIA = Radioimmunoassay. iPD = 
idiopathic PD patients, LRRK2 PD = patients with the LRRK2 mutation. LDopa = patients receiving levodopa medication, only used when the 
PD group is split into those who are receiving treatment and those who are not. () = males only, {} = females only. Studies highlighted in grey 
indicate LBD, all other studies investigate PD only.  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Table 2 
Study 
Number of 
participants 
 Disease 
duration 
(years) Age (years) Method used 
Pro-inflammatory Variable Anti-inflammatory 
IL-1alpha IL-1beta IL-2 IL-8 IL-12 
TNF-
alpha 
INF-
gamma IL-6 
TGF-
beta1 IL-4 IL-10 
Martin de 
Pablos 2015 
(48) 
29 PD 
21 controls 
Not 
specified 
PD: 63.4 
controls:67.9 
ELISA 
(lumbar) 
             
↑** 
    
Mogi 1995 (24) 
& Mogi 1996 
(25) 
14 PD 
13 control 
Not 
specified 
PD: 68.0 
Control:46.0 
ELISA 
(ventricular)  
NS 
 
↑* 
        
↑* 
 
↑** 
 
NS 
  
Rota 2006 (29) 
 
14 PD 
25 Controls 3.0 
PD: 66.0 
Control: 69.0 ELISA     NS    NS  NS 
10 PDD 7.2 PDD: 69.0 ELISA     NS    NS  NS 
Hu 2015 (36) 
225 PD 
31 control 
2.2 
 
PD: 59.0 
Control: Matched 
ELISA 
(lumbar) 
  
↑* 
    
NS 
      
Hu  2015 (37) 
210 PD 
31 control 
2.3 
 
60.2 
Control: Matched 
ELISA 
(lumbar) 
  
↑*** 
(PRBD)      
NS 
          
Blum-Degen 
1995 (19) 
22 PD 
12 Control 
0.5-3.0 
 
PD: 61.0 
Control: 61.0 
ELISA 
(lumbar) 
  
↑* 
 
NS 
        
↑* 
     
Pirttila 1994 
(14) 
20 PD 
42 control 
New 
onset 
PD: 64.6 
control: 60.9 
ELISA 
(lumbar) 
  
NS 
          
Mogi 1994 (44) 
15 PD 
16 controls 
Not 
specified 
PD: 58  
Control: 46 
Sandwich EIA 
(lumbar)      
↑** 
      
Muller  1998 
(45) 
22 PD 
44 controls 
Not 
specified 
PD: 61.0 
Control: Matched 
ELISA 
(lumbar) 
        
↑* 
    
Yu 2014 (46) 26 PD 
31 controls 
2.0 
 
PD: 57.4 
Controls: 52.2 
ELISA 
(lumbar) 
  ↑*       NS ↓* NS     
3 PDD 
33 PD-MCI 3.0 PD-CI:61.1 
ELISA 
(lumbar)  ↑***    ↓** ↓** ↑*    
 
lindvquist 2013 
(17) 
71 PD 
33 control 
PD:6.4 
 
PD: 64.2 
Control: 65.8 
MSD (lumbar) 
         
NS 
   
NS 
     
16 PDD 15.8 PDD: 70.0 MSD (lumbar)      NS  NS    
Janelidze 2015 
(47) 
82 PD 
38 control 
6.5 
 
PD: 64.5 
Control: 65.4 
ELISA 
(lumbar) 
      
NS 
            
18 PDD 16.3 PDD: 72.3 
ELISA 
(lumbar)    ↑*        
Wennstrom 
2015 (6) 
29 DLB 
36 control 
Not 
specified 
DLB: 74.0 
Control: 62.0 MSD (lumbar)        ↓**    
Gomez-Tortosa 
2003 (49) 
25 DLB 
46 control 2.25 
DLB: 75.2 
Controls: 72.7 
ELISA 
(lumbar)  
NS 
      
NS 
    
Choi 2008 (11) 
8 PD 
13 Control De novo 
PD: 73.0 
Control: 68.5 
Luminex 
xMAP 
NS 
 
ND 
 
ND 
 
ND 
  
ND 
 
ND 
 
ND 
 
ND 
 
ND 
  
 
Table 2: All studies investigating cytokine levels in CSF. It is indicated whether there is a significant increase or decrease, where * = p < 0.05, 
** = p < 0.01, *** = p < 0.001, NS = non-significant and ND = cytokine not detected. ELISA = Enzyme-linked immunosorbent assay, EIA = 
Enzyme Immunoassay, MSD = Meso Scale Discovery. (PRBD) = Probable REM sleep behavioural disorder patients only. Studies highlighted 
in grey indicate LBD, all other studies investigate PD only.  
 
 
 
 
Table 3 
Study Biofluid Number of participants Disease duration (years) Age (years) CRP vs control 
Akil 2015 (54) Blood 
51 PD 
50 controls 
6.1 
 
PD: 69.5 
Control:65.9 
↑** 
 
Andican 2012 (51) Blood 
45 PD 
25 controls 
6.4 
 
PD: 63.6 
Controls:60.2 
NS 
 
Lindqvist 2012 (52) Blood 
86 PD 
40 controls 
6.9 
 
PD: 64.2 
Controls: 64.8 
NS 
 
Lindqvist 2013 (17) CSF 71 PD 
33 control 
6.4 
 
PD: 64.2 
Control: 65.8 
NS 
 
16 PDD 15.8 PDD: 70.0 ↑* 
Sawada 2014 (53) Blood 
111 PD 
53 controls 
8.0 
 
PD: 69.7 
Control: 69.1 
NS 
 
Song 2009 (20) Blood 
212 PD 
119 controls 
2.1 
 
PD: 68.7 
Controls: 66.6 
↑** 
 
Song 2011 (21) Blood 
63 PD 
117 controls 
1.0 
 
PD: 63.7 
Controls: 66.6 
↑** 
 
  
Table 3: All studies investigating CRP levels. It is indicated whether there is a significant increase or decrease, where * = p < 0.05, ** = p < 
0.01, *** = p < 0.001 and NS = non-significant. 
 
 
 
Song 2013 (16) Blood 72 PD 
84 control 
SYMPTOM duration 1.6 
 
PD: 69.7 
controls:73.2 
↑*** 
 
45 PDD 1.9 PDD:71.4 ↑*** 
Song 2014 (10) Blood 
435 PD 
221 controls 
SYMPTOM duration 2.3 
 
PD: 69.4 
controls: 68.5 
↑*** 
 
Umemura 2015 (55) Blood 
375 PD 
65 controls 
6.6 
 
PD: 69.3 
Control: 63 
↑** 
 
Williams-Gray 2016  (40) Blood 
230 PD 
93 controls 
0.6 
 
PD: 66.4 
controls: 68.0 
NS 
 
